Vascular Disease in Scleroderma: Mechanisms of Vascular Injury

Rheumatic Disease Clinics of North America

Volumn 34, Issue 1, 2008, Pages 57-71

  Kahaleh, Bashar ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIN; NITRIC OXIDE; VON WILLEBRAND FACTOR;

APOPTOSIS; ARTERIOLE; BLOOD CLOTTING; BLOOD VESSEL; BLOOD VESSEL INJURY; CHEMICAL MODIFICATION; DISEASE SEVERITY; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRINOLYSIS; HUMAN; IMMUNOSTIMULATION; ISCHEMIA; MICROCIRCULATION; MICROVASCULATURE; ORGAN BLOOD FLOW; PHYSIOLOGY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REPERFUSION INJURY; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; THROMBOCYTE; TISSUE PERFUSION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VIRUS INFECTION; VIRUS REPLICATION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AUTOANTIBODIES; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; HUMANS; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 40149083876     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.12.004     Document Type: Review

References (68)

1. Norton W.L., and Nardo J.M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73 (1970) 317-324
2. Fleischmajer R., and Perlish J.S. Capillary alterations in scleroderma. J Am Acad Dermatol 2 (1980) 161-170
3. Brown G.E., and O'Leary P.A. The skin capillaries in Raynaud's disease. Arch Intern Med 36 (1925) 161-170
4. Maricq H.R., Leroy E.C., and D'Angelo W.A. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23 (1980) 183-189
5. Fleischmajer R., Perlish J.S., Shaw K.V., et al. Skin capillary changes in early systemic scleroderma: electron microscopy and "in vitro" autoradiography with tritiated thymidine. Arch Dermatol 112 (1976) 1553-1557
6. Freemont A.J., Hoyland J., Fielding P., et al. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126 (1992) 561-568
7. Grassi W., Core P., Carlino G., et al. Labial capillary microscopy in systemic sclerosis. Ann Rheum Dis 52 (1993) 564-569
8. Sgnonc R., Gruschwitz M.S., Dietrich H., et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98 (1996) 785-792
9. Chen F., Eriksson P., Kimura T., et al. Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coron Artery Dis 16 3 (2005) 191-197
10. Mitra D., Steiner M., Staiano-Coico L., et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 87 8 (1996) 3245-3254
11. Francisco L.M., Sauter B., Roy P., et al. Immature dendritic cells phagocytose apoptotic T lymphocytes. J Exp Med 88 (1998) 1359-1368
12. Greeno E.W., Bach R.R., and Moldow C.F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 75 2 (1996) 281-289
13. Tsuji S., Kaji K., and Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J Biochem 116 4 (1994) 794-800
14. Pandey J.P., and LeRoy E.C. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 41 1 (1998) 10-15
15. Zaia J.A. Epidemiology and pathogenesis of cytomegalovirus disease. Semin Hematol 2 (1990) 5-10
16. Lunardi C., Bason C., Corrocher R., et al. Induction of endothelial cell damage by hCMV molecular mimicry. Trends Immunol 26 1 (2005) 19-24
17. Madge L.A., Li J.H., Choi J., et al. Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem 278 23 (2003) 21295-21306
18. Waldman W.J., Knight D.A., and Adams P.W. Cytolytic activity against allogeneic human endothelia: resistance of cytomegalovirus-infected cells and virally activated lysis of uninfected cells. Transplantation 66 1 (1998) 66-67
19. Kahaleh M.B., and Fan P.S. Mechanism of serum mediated endothelial injury in scleroderma: identification of granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83 (1997) 32-40
20. Kahaleh M.B., Fan P.S., and Otsuka T. Gamma delta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 91 2 (1999) 188-195
21. Sgonc R., Gruschwitz M.S., Boeck G., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43 11 (2000) 2550-2562
22. Wusirika R., Ferri C., Marin M., et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. Am J Clin Pathol 120 4 (2003) 596-606
23. Belizna C., Duijvestijn A., Hamidou M., et al. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis 65 12 (2006) 1545-1550
24. Pignone A., Scaletti C., Matucci-Cerinic M., et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16 5 (1998) 527-532
25. Negi V.S., Tripathy N.K., Misra R., et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25 (1998) 462-466
26. Carvalho D., Savage C.O., Black C.M., et al. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro: induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97 1 (1996) 111-119
27. Bordron A., Dueymes M., Levy Y., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 101 10 (1998) 2029-2035
28. Worda M., Sgonc R., Dietrich H., et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorioallantoic membrane assay. Arthritis Rheum 48 (2003) 2605-2614
29. Garcia de la Pena-Lefebvre P., Chanseaud Y., Tamby M.C., et al. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clin Immunol 111 3 (2004) 241-251
30. Ahmed S.S., Tan F.K., Arnett F.C., et al. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 54 7 (2006) 2250-2262
31. Magro C.M., Ross P., Marsh C.B., et al. The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 127 2 (2007) 237-247
32. Christen S., Finckh B., Lykkesfeldt J., et al. Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med 38 10 (2005) 1323-1332
33. Bohm F., Settergren M., Gonon A.T., et al. The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. Clin Sci (Lond) 108 4 (2005) 357-363
34. Szocs K. Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance. Gen Physiol Biophys 23 3 (2004) 265-295
35. Fox-Robichaud A., Payne D., Hasan S.U., et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 101 11 (1998) 2497-2505
36. Lehmann T.G., Koeppel T.A., Kirschfink M., et al. Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation 66 (1998) 717-722
37. Collard C.D., Agah A., and Stahl G.L. Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-kappa B and new protein synthesis. Immunopharmacology 39 1 (1998) 39-50
38. Fullerton D.A., Eisenach J.H., Friese R.S., et al. Impairment of endothelial-dependent pulmonary vasorelaxation after mesenteric ischemia/reperfusion. Surgery 120 5 (1996) 879-884
39. Gabrielli A., Di Loreto C., Taborro R., et al. Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 68 3 (1993) 340-349
40. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
41. Inoue A., Yanagisawa M., and Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86 (1989) 2863-2867
42. Kahaleh M.B. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 34 (1991) 978-983
43. Yamane K., Miyanchi T., Suzuki N., et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19 (1992) 1566-1571
44. Vancheeswaran R., Azam A., Black C., et al. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 21 7 (1994) 1268-1276
45. Clozel M., and Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 37 1 (2005) 2-12
46. Korn J.H., Mayes M., Matucci-Cerinic M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
47. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 12 (2002) 896-903
48. Bush P.A., Gonzalez N.E., Griscavage J.M., et al. Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from l-arginine. Biochem Biophys Res Commun 185 (1992) 960-966
49. Kuo L., Davis M.J., and Chilian W.M. Endothelial modulation of arteriolar tone. News Physiol Sci 7 (1992) 5-9
50. Wanstall J.C., Homer K.L., and Doggrell S.A. Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 3 1 (2005) 41-53
51. Anderson M.E., Moore T.L., Hollis S., et al. Endothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis. Clin Exp Rheumatol 21 3 (2003) 403
52. Tmito M., Fan P., Santoro T., et al. Impaired response to mechanical fluid shear stress (MFSS) by scleroderma (SSc) microvascular endothelial cells (MVEC) from involved and uninvolved skin. Arthritis Rheum 40 (1997) S297
53. Berk B.C., Abe J.I., Min W., et al. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci 947 (2001) 93-109
54. Kahaleh M.B., Osborn I., and LeRoy E.C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 96 (1982) 610-613
55. Falanga V., and Alstadt S.P. Effect of a platelet release fraction on glycosaminoglycan synthesis by cultured dermal fibroblasts from patients with progressive systemic sclerosis. Br J Dermatol 118 (1988) 339-345
56. Mattuci-Cerinic M., Valentinie G., Sorano G.G., et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32 5 (2003) 285-295
57. Kahaleh M.B., Osborn I., and LeRoy E.C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 94 (1981) 482-484
58. Herrick A.L., Illingworth K., Blann A., et al. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 55 2 (1996) 122-127
59. Greaves M., Malia R.G., Milford Ward A., et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol 27 4 (1988) 281-285
60. Matucci-Cerinic M., Pignone A., Iannone F., et al. Clinical correlations of plasma angiotensin converting enzyme (activity in systemic sclerosis): a longitudinal study of plasma ACE endothelial injury and lung involvement. Respir Med 84 4 (1990) 283-287
61. Stratton R., Pompon L., Coghlan J., et al. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 59 2 (2000) 132-134
62. Mizutani H., Hayashi T., Nouchi N., et al. Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. Acta Med Okayama 50 6 (1996) 293-297
63. Matucci-Cerinic M., Borsotti M., Barbieri R., et al. Angiotensin converting enzyme (ACE) in scleroderma. Clin Rheumatol 6 2 (1987) 300-301
64. Matucci-Cerinic M., Jaffa A., and Kahaleh B. Angiotensin converting enzyme: an in vivo and in vitro marker of endothelial injury. J Lab Clin Med 120 3 (1992) 428-433
65. Carson C.W., Beall L.D., Hunder G.G., et al. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 20 5 (1993) 809-814
66. Sfikakis P.P., Tesar J., Baraf H., et al. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68 1 (1993) 88-92
67. Oppenheimer-marks N., Davis L.S., and Lipsky P.E. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 147 (1991) 398-321
68. Del Papa N., Colombo G., Fracchiolla N., et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50 4 (2004) 1296-1304